What's Happening?
Thryv Therapeutics Inc., a clinical-stage biopharmaceutical company, has secured an exclusive, worldwide, royalty-bearing patent and know-how license agreement with the Spanish National Research Council (CSIC), the Autonomous University of Madrid (UAM),
and Fundación de la Universidad Autónoma de Madrid (FUAM). This agreement, effective July 1, 2026, grants Thryv rights across all fields of use and territories, including sublicensing. The license pertains to a new class of SGK1 inhibitors, representing a distinct chemical scaffold from Thryv's existing portfolio. This new series was developed by research groups with expertise in medicinal chemistry, cardiovascular research, neurobiology, and vascular pharmacology. The kinase SGK1 is implicated in various neurodegenerative processes, including tau phosphorylation, the handling of misfolded and aggregating proteins, neuroinflammatory signaling, and cellular stress responses.
Why It's Important?
This licensing agreement is significant for Thryv Therapeutics as it expands its platform into neurodegenerative diseases, specifically targeting conditions like Parkinson's disease, Alzheimer's disease, and related tauopathies. By acquiring a second, structurally distinct chemical scaffold for SGK1 inhibitors, Thryv gains the ability to tailor its chemistry to specific indications. This allows for continued optimization of existing molecules for cardiac and cardiometabolic diseases while simultaneously developing compounds specifically designed to reach the brain for neurological applications. The involvement of SGK1 in critical neurodegenerative pathways, such as tau phosphorylation and neuroinflammatory signaling, suggests a promising avenue for developing novel therapeutic interventions for these debilitating conditions, potentially offering new hope for patients and their families.
What's Next?
Thryv Therapeutics will now focus on developing compounds from this newly licensed series that are specifically designed to penetrate the brain, aiming to address the complex challenges of neurodegenerative diseases. The company plans to continue optimizing its current SGK1 inhibitor candidates for cardiac and cardiometabolic diseases while simultaneously advancing this new neurodegeneration-focused program. This dual approach suggests a strategic expansion of Thryv's pipeline, potentially leading to new clinical trials for neurodegenerative indications. Future steps will likely involve preclinical development, followed by human clinical trials, to assess the safety and efficacy of these new SGK1 inhibitors in treating conditions like Parkinson's and Alzheimer's diseases.
Beyond the Headlines
The acquisition of this new class of SGK1 inhibitors highlights a growing trend in pharmaceutical research: the exploration of multi-faceted biological targets for complex diseases. SGK1's involvement in multiple pathways central to neurodegeneration – from protein aggregation to neuroinflammation – suggests that targeting this kinase could offer a comprehensive therapeutic strategy rather than addressing a single symptom. This approach could lead to more effective treatments for neurodegenerative diseases, which currently have limited curative options. Furthermore, the collaboration between a U.S. biopharmaceutical company and Spanish research institutions underscores the global nature of scientific innovation and the importance of international partnerships in advancing medical breakthroughs.
